Bellaver, Bruna http://orcid.org/0000-0002-2212-3373
Povala, Guilherme http://orcid.org/0000-0002-2023-6569
Ferreira, Pamela C. L. http://orcid.org/0000-0003-2134-9829
Ferrari-Souza, João Pedro
Leffa, Douglas T.
Lussier, Firoza Z.
Benedet, Andréa L.
Ashton, Nicholas J.
Triana-Baltzer, Gallen
Kolb, Hartmuth C.
Tissot, Cécile http://orcid.org/0000-0003-2711-3833
Therriault, Joseph http://orcid.org/0000-0002-7826-4781
Servaes, Stijn
Stevenson, Jenna
Rahmouni, Nesrine
Lopez, Oscar L. http://orcid.org/0000-0002-8546-8256
Tudorascu, Dana L.
Villemagne, Victor L.
Ikonomovic, Milos D.
Gauthier, Serge
Zimmer, Eduardo R.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Aizenstein, Howard J.
Klunk, William E.
Snitz, Beth E.
Maki, Pauline
Thurston, Rebecca C. http://orcid.org/0000-0001-6580-1202
Cohen, Ann D.
Ganguli, Mary
Karikari, Thomas K.
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Pascoal, Tharick A. http://orcid.org/0000-0001-9057-8014
Article History
Received: 23 January 2023
Accepted: 1 May 2023
First Online: 29 May 2023
Competing interests
: H.C.K. and G.T.-B. are employees and stockholders of Johnson & Johnson. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. S.G. has served as a scientific advisor to Cerveau Therapeutics. E.R.Z. serves on the scientific advisory board of Next Innovative Therapeutics (Nintx). P.R.-N. has served on scientific advisory boards and/or as a consultant for Eisai, Novo Nordisk and Roche. N.J.A. has given lectures in symposia sponsored by Lilly and Quanterix. M.D.I. has received research funding from GE Healthcare and Avid Radiopharmaceuticals. R.C.T. serves as a consultant, advisor and/or on the medical advisory board of Happify Health, Astellas Pharma, Bayer and Hello Therapeutics. GE Healthcare holds a license agreement with the University of Pittsburgh based on the PiB PET technology described in this paper. W.E.K. is a co-inventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this paper. The other authors declare no competing interests.